La porte monumentale de Chéchanq III : Rapport préliminaire 1996 = The monumental door of Sheshonq III: preliminary report 1996HAIRY, I.Bulletin de la Société française des fouilles de Tanis. 1995, Num 9, pp 51-69, issn 1268-4481, 15 p.Article

Design Issues in Randomized Phase II/III TrialsKORN, Edward L; FREIDLIN, Boris; ABRAMS, Jeffrey S et al.Journal of clinical oncology. 2012, Vol 30, Num 6, pp 667-671, issn 0732-183X, 5 p.Article

CLINICAL TRIALSOF NEW DRUGS.DOLLERY CT; WADE OL; TURNER P et al.1977; J. R. COLL. PHYSICIANS LONDON; G.B.; DA. 1977; VOL. 11; NO 3; PP. 226-233; BIBL. 1 REF.Article

The benefits of participation in clinical trialsVAN DONGEN, J. A; VAN DE VELDE, C. J. H.European journal of surgical oncology. 1996, Vol 22, Num 6, pp 561-562, issn 0748-7983Article

Time to mandate data release and independent audits for all clinical trialsHAINES, Ian E; GABOR MIKLOS, George L.Medical journal of Australia. 2011, Vol 195, Num 10, pp 575-577, issn 0025-729X, 3 p.Article

Comment faire évoluer le paradigme du développement clinique et son découpage en phases I, II, IIIBAMBERGER, Marion; MOORE, Nicholas; LECHAT, Philippe et al.Thérapie (Paris). 2011, Vol 66, Num 4, pp 327-330, issn 0040-5957, 4 p.Article

Fast recruiting clinical trials : a Utopian dream or logistical nightmare?JOHNSON, L; ELLIS, P; BLISS, Jm et al.British journal of cancer. 2005, Vol 92, Num 9, pp 1679-1683, issn 0007-0920, 5 p.Article

MANAGEMENT OF TRIALS IN THE DEVELOPMENT OF CANCER CHEMOTHERAPY.WILLIAMS CJ; CARTER SK.1978; BRIT. J. CANCER; GBR; DA. 1978; VOL. 37; NO 3; PP. 434-447; BIBL. 24 REF.Article

Assessing the success probability of a Phase III clinical trial based on Phase II dataZHENG SU.Contemporary clinical trials. 2010, Vol 31, Num 6, pp 620-623, issn 1551-7144, 4 p.Article

Journées de pharmacogie cliniqueThérapie (Paris). 1992, Vol 47, Num 5, pp 455-465, issn 0040-5957Conference Proceedings

Phase II/III randomized trial of TCH346 in patients with ALSMILLER, R; BRADLEY, W; STRONG, M et al.Neurology. 2007, Vol 69, Num 8, pp 776-784, issn 0028-3878, 9 p.Article

Phase II Trial of CoQ10 for ALS Finds Insufficient Evidence to Justify Phase IIIKAUFMANN, Petra; THOMPSON, John L. P; TIRYAKI, Ezgi et al.Annals of neurology. 2009, Vol 66, Num 2, pp 235-244, issn 0364-5134, 10 p.Article

Les Fils Royaux de Ramsès : Une nouvelle hypothèse = The Royal sons of Ramses : a new hypothesisCOLLOMBERT, P.Göttinger Miszellen. 1996, Num 151, pp 23-35, issn 0344-385XArticle

On the design of the phase III drug trial. The example of rheumatoid arthritisHADLER, N. M; GILLINGS, D. B.Arthritis and rheumatism. 1983, Vol 26, Num 11, pp 1354-1361, issn 0004-3591Article

MR angiography of aortoiliac occlusive disease : A phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325GOYEN, Mathias; EDELMAN, Mark; KENT YUCEL, E et al.Radiology. 2005, Vol 236, Num 3, pp 825-833, issn 0033-8419, 9 p.Article

What are the reasons for negative phase III trials of molecular-target-based drugs?SAIJO, Nagahiro.Cancer science. 2004, Vol 95, Num 10, pp 772-776, issn 1347-9032, 5 p.Article

The ethical position of the attending physician in phase III of clinical investigationsVON EICKSTEDT, K.-W.International journal of clinical pharmacology, therapy and toxicology (1980). 1983, Vol 21, Num 10, pp 529-534, issn 0174-4879Article

Inference of Unexpected Genetic Relatedness among Individuals in HapMap Phase IIIPEMBERTON, Trevor J; CHAOLONG WANG; LI, Jun Z et al.American journal of human genetics. 2010, Vol 87, Num 4, pp 457-464, issn 0002-9297, 8 p.Article

The importance of reporting patient recruitment details in phase III trialsWRIGHT, James R; BOUMA, Sarah; DAYES, Ian et al.Journal of clinical oncology. 2006, Vol 24, Num 6, pp 843-847, issn 0732-183X, 5 p.Article

Guidelines for clinical evaluation of antiepileptic drugsEpilepsia (Copenhagen). 1989, Vol 30, Num 4, pp 400-408, issn 0013-9580Article

Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acidGREM, J. L; HOTH, D. F; HAMILTON, J. M et al.Cancer treatment reports. 1987, Vol 71, Num 12, pp 1249-1264, issn 0361-5960Article

Novel endpoints and design of early clinical trialsPARULEKAR, W. R; EISENHAUER, E. A.Annals of oncology. 2002, Vol 13, pp 139-143, issn 0923-7534, 5 p., SUP4Conference Paper

The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agentsROWINSKY, Eric K.Drugs (Basel). 2000, Vol 60, pp 1-14, issn 0012-6667, SUP1Article

How to Improve the Clinical Development Paradigm and its Division into Phases I, II and IIIBAMBERGER, Marion; MOORE, Nicholas; LECHAT, Philippe et al.Thérapie (Paris). 2011, Vol 66, Num 4, pp 331-334, issn 0040-5957, 4 p.Article

The out-of-focus bias in drug surveillanceGNÄDINGER, Markus; MELLINGHOFF, Hans-Ulrich.European journal of clinical pharmacology. 2013, Vol 69, Num 3, pp 357-359, issn 0031-6970, 3 p.Article